Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group, Inc. reports clinical, regulatory and financial developments for a clinical-stage biotechnology business developing oncolytic immunotherapies for cancer. The company’s proprietary RPx platform uses an engineered HSV-1 backbone intended to promote tumor cell killing, immunogenic cell death and systemic anti-tumor immune responses.
Recurring Replimune news centers on RP1, or vusolimogene oderparepvec, including data from the IGNYTE clinical trial, combination use with nivolumab in advanced melanoma, Biologics License Application activity and FDA complete response letters. Updates also cover RP2 clinical data in advanced solid tumors, scientific presentations at oncology meetings, quarterly financial results, research and development spending, cash runway commentary and management presentations at healthcare conferences.
Replimune Group Inc. (NASDAQ: REPL) announced the resignation of Otello Stampacchia, Ph.D., from its Board of Directors effective January 31, 2022. Dr. Stampacchia, a co-leader of Replimune’s seed financing, has decided to focus on his commitments at Omega Funds. CEO Philip Astley-Sparke expressed gratitude for Dr. Stampacchia’s contributions to Replimune's growth from inception to a leader in oncolytic immunotherapies. Replimune aims to innovate cancer treatment through its proprietary RPx platform, enhancing both local and systemic therapeutic effects.
Replimune Group (Nasdaq: REPL) provided a corporate update on January 10, 2022, highlighting the progress of its clinical trials for RP1, RP2, and RP3. The CERPASS trial for RP1 in cutaneous squamous cell carcinoma (CSCC) is on track for enrollment completion mid-year, leading to primary data analysis later. Interim data from the IGNYTE trial, assessing RP1's efficacy in anti-PD1 failed melanoma, is expected by late 2022. Replimune aims to expand RP2 and RP3 trials into diverse cancer types, with detailed development plans to be unveiled in Q1 2022.
Replimune Group, a clinical-stage biotechnology firm, has announced that its CEO, Philip Astley-Sparke, will present on January 10, 2022, at the 40th Annual J.P. Morgan Healthcare Conference. The event will be held virtually at 7:30 AM ET. A webcast will be accessible through Replimune’s website, with a replay available for 30 days. Founded in 2015, Replimune focuses on tumor-directed oncolytic immunotherapies, utilizing its proprietary RPx platform to enhance cancer treatment.
Replimune Group, Inc. (Nasdaq: REPL) has appointed Christy Oliger to its Board of Directors effective December 1, 2021. Oliger brings nearly 30 years of pharmaceutical and biotechnology experience, particularly in oncology, having previously held key roles at Genentech. CEO Philip Astley-Sparke expressed optimism about Oliger's contributions to the company’s leading pipeline of oncolytic immunotherapies. Replimune focuses on advancing its innovative immuno-gene therapy platform aimed at enhancing cancer treatment.
Replimune Group (Nasdaq: REPL) announced updated interim data from its Phase 1 trial of RP2, demonstrating strong responses in difficult-to-treat cancers. The trial includes both RP2 as a monotherapy and in combination with Opdivo. Notable findings include durable responses in patients with esophageal and mucoepidermoid carcinoma lasting 19-22 months. The 30-patient cohort with Opdivo showed a 23.3% partial response rate, with ongoing responses exceeding 425 days. The company plans to enroll an additional 24 patients with liver metastases in response to positive results.
Replimune Group (NASDAQ: REPL) reported a net loss of $29.4 million for Q2 2021, up from $20.1 million in Q2 2020. R&D expenses increased to $19.9 million, driven by expanded clinical programs. The company maintains a strong cash position of approximately $436 million, expected to fund operations into H2 2024. Full patient accrual in the CERPASS trial is anticipated by mid-2022, with primary data trigger expected by late 2022. Initial data from the IGNYTE trial is also set for late 2022, reinforcing Replimune's focus on establishing a robust skin cancer franchise.
Replimune Group, Inc. (NASDAQ: REPL) announced upcoming presentations at two key conferences. The first, BMO Biopharma Spotlight Series, occurs on November 8, 2021, focusing on next-gen oncolytic virus therapies. The second event, Piper Sandler 33rd Virtual Annual Healthcare Conference, runs from November 30 to December 2, 2021, featuring a pre-recorded fireside chat available on-demand starting November 22. Replimune develops innovative oncolytic immuno-gene therapies using its Immulytic® platform to enhance cancer treatment.
Replimune Group, Inc. (Nasdaq: REPL) announced four poster presentations at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, scheduled for November 10-14, 2021. Key presentations include:
- RP2: Phase 1 trial with nivolumab for advanced solid tumors.
- ARTACUS: Phase 1b/2 study on RP1 in transplant recipients.
- CERPASS: Phase 2 study of cemiplimab ± RP1 for advanced squamous cell carcinoma.
- IGNYTE: Phase 1/2 trial of RP1 ± nivolumab in advanced tumors.
Full posters will be available on Replimune's website.
Replimune Group, Inc. (NASDAQ: REPL) announced updates on its ongoing clinical trials and financial results for Q1 2021. The company reported cash reserves of $458 million, sufficient to fund activities into H2 2024. Data for RP1 and RP2 indicate durable responses in advanced skin cancers, supporting ongoing trials, including the CERPASS study for cutaneous squamous cell carcinoma (CSCC). A Phase 2 program focusing on liver metastases is being designed, with plans to disclose details in early 2022. R&D expenses rose to $18.6 million, with a net loss of $27.3 million for the quarter.
Replimune Group (NASDAQ: REPL) announced that its management will present at two upcoming virtual conferences. The BTIG Virtual Biotechnology Conference is scheduled for August 9, 2021, at 11:00 am ET. The second event, the 2021 Wedbush PacGrow Healthcare Virtual Conference, will include a panel discussion on immuno-oncology challenges on August 11, 2021, at 12:35 pm ET. Replimune is focused on developing oncolytic immune-gene therapies to enhance cancer treatment effectiveness through its Immulytic® platform.